Kader Thiam

Company: genOway
Job title: Vice President of Transgenic Technologies
Seminars:
Immune Checkpoints; Humanised Preclinical Models for Biologics’ Efficacy & MoA 2:45 pm
Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomesRead more
day: Day One
Panel Discussion: Limitations of Humanised & PDX Models 2:00 pm
How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells? Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground? Gaining data on persistence of cellular therapies without requiring additional miceRead more
day: Day One